A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigationa…
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly used worldwide for weight loss and glycaemic control but is associated with gastrointestinal side effects. We her…
BACKGROUND: The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. This systematic review and network met…
AIMS: Tirzepatide reduced weight significantly more than placebo in adults with obesity/overweight who had already achieved ≥5% weight reduction with a 12-week intensive lifestyle intervention (randomized population) in SURMOUNT-3, a phase 3, 72-week…
Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separate…
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diab…
BACKGROUND: Tirzepatide reduced weight and improved cardiometabolic risk factors for participants in the SURMOUNT-1 trial. The changes in cardiometabolic risk factors by degree of tirzepatide-induced weight reduction across a wide spectrum of weight…
BACKGROUND: Body weight and health-outcome results of highly effective new GLP-1R agonist medicine trials are usually presented in scientific reports in the form of standard graphs and tables. These representations are not easily translated to what t…
PURPOSE: This study aims to investigate the possible impacts of fasting on physical activity and weight loss in adult users of glucagon-like peptide-1 (GLP-1) agonists, specifically semaglutide and tirzepatide, using qualitative methods to gain in-de…
OBJECTIVE: Previous experiments have demonstrated that BGM0504, a GLP-1R/GIPR dual agonist drug by molecular dynamics-guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims to investigate its safety, tolerabilit…
OBJECTIVES: Dual glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor agonists (GLP1RA and GIPRA, respectively) synergise to reduce body weight. Though this synergy depends on receptors within the brain, where an…
Semaglutide and tirzepatide represent new treatment modalities for type 2 diabetes mellitus (T2DM) and obesity, expanding the range of glucagon-like peptide-1 (GLP-1) receptor agonists. Semaglutide is a GLP-1 receptor analog while tirzepatide is a du…
AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multic…
INTRODUCTION: Obesity is a major health crisis globally, with prevalence escalating significantly in recent decades. Obesity is not merely excessive weight but is associated with myriad health complications. Ensuring the translational effectiveness o…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastr…